CROs in the Age of AI

Part 4: What Comes Next for CROs in an AI-Driven Market

Over the past few months, we’ve looked at how AI is changing clinical research, how CROs are investing, and how leadership teams are starting to operationalize these changes. The next step is understanding how all of this reshapes the market.

Sponsors are already adjusting how they evaluate CRO partners. Scale and experience still matter, but expectations now include faster timelines, more efficient operations, stronger data quality, and clearer insights.

That shift is starting to influence broader market dynamics.

Capitalization cycles are changing. Investors are placing more weight on AI and data capabilities when evaluating CROs. Organizations that can show clear differentiation are more likely to attract investment, while others may face pressure on valuation and growth.

Consolidation pressure is increasing. Partnerships and acquisitions are becoming more common as CROs and technology providers look to expand capabilities and stay competitive.

Competitive positioning is shifting. As automation reduces reliance on traditional labor, organizations need to rethink how they balance cost, talent, and delivery to maintain an advantage.

All of this leads to a simple question for leadership teams: How will your organization compete as AI becomes part of the baseline?

For many CROs, the answer comes down to a few practical steps:

1. Take a clear look at current readiness across data, processes, and governance

2. Focus on a small number of business problems where AI can create measurable value

3. Move beyond pilots and build programs that change how work gets done.

AI adoption is not a one-time initiative. It is an ongoing shift in how organizations operate and create value. The CROs that make steady, focused progress now will be in a much stronger position over the next few years. If you’d like a deeper look at how these changes are playing out, you can read the full executive viewpoint below.